Risk of being exposed or dying of covid. 0ne hopes that in the international stage, similarly, the right people will make decisions swiftly.- the right people will make decisions swiftly. israel says it is in talks decisions swiftly. israel says it is in talks with decisions swiftly. israel says it is in talks with other - it is in talks with other countries to offload its surplus vaccines and that pfizer would have to approve any deal. a pfizer spokesperson says the company is happy to discuss potential donation requests of the pfizer biontech covid vaccine on a case by case basis particularly if this helps ensure the vaccine is used to protect people from this disease. this disease. the countries that have this disease. the countries that have the this disease. the countries that have the financial- this disease. the countries i that have the financial muscle to do so have ordered many more doses of vaccine than they actually need, and there is clearly a need for agility and
Variant. however, there is a bit of a caveat with theirs. these 78,000 results are not confirmed omicron cases, therefore the world health organization is saying it is not able to draw conclusive findings about this variant, labelled of concern by the who. but the initial studies in the two doses of the pfizer biontech covid vaccine appear to have given 70% protection against hospitalisation in south africa in recent weeks. of course, a lot of people looking to the data coming out of south africa to see exactly how much we need to be worried about this particular variant. one of the measures that will be voted on will allow fully vaccinated people who have been exposed to a positive covid case to avoid self isolation if they take daily lateral flow tests and receive a negative result. this one isn t expected to provoke a rebellion among conservative backbenchers.
Sure the vaccines we have to stay ahead of the curve and we don tjust keep buying lots and lots and lots of vaccine against wuhan when actually we need to start thinking about what these new variants look like. if that means three doses, thatis like. if that means three doses, that is what we need to do now but that is what we need to do now but thatis that is what we need to do now but that is not adequate going forward. if you look at the public accounts committee report, the cost of deployment last year when i was in post was about the same as the cost of buying the vaccines we bought last year, so we cannot be in a position where we have to go through this monumental logistics challenge of getting vaccines into arms, so the other area we must push forward is how do we improve the format of these vaccine so they are much easier and cheaper to deploy? whether that is patches, sprays, whatever, we need to find the
The tent who know exactly what is happening, but if i was glad now, i would be absolutely focusing my attention is under energies on the advancement and manufacturing and skills and process development capability and notjust on procurement. capability and not ust on procurement. capability and not ust on procurement. capability and not ust on rocurement. ., ,, , ., ., ., procurement. thank you. how worried which ou procurement. thank you. how worried which you have procurement. thank you. how worried which you have been procurement. thank you. how worried which you have been about procurement. thank you. how worried which you have been about omicron i which you have been about omicron were you which you have been about omicron were you still reading the vaccine task for were you still reading the vaccine task for the? of were you still reading the vaccine task for the? were you still reading the vaccine task for the? , , , . task for the? of course we expected variants.
Partner was to have that capability to grow up variance vaccines. it is not trivial and not every virus can be grown, but that is one of the ideas of how would you get ahead of the mutations of the vaccine. it may be it has been done, i certainly read in the press that different vaccine companies are creating omicron variants but that is what i think we should be doing both historically and what we should do in the future is predicting what they will be at making vaccines accordingly. the testing, we have the capability to test head how effective the vaccines are against these. ourfocus last effective the vaccines are against these. our focus last year was very much on speed, it was not about getting the perfect vaccine. what has become clear is the rate of mutation here is quite rapid so